Enzon to add independent board member under agreement with DellaCamera

By Lisa Kerner

Charlotte, N.C., Feb. 12 - DellaCamera Capital Master Fund, Ltd. entered into an agreement with Enzon Pharmaceuticals, Inc. providing for the addition of a new, independent member to the company's board of directors.

As a result, DellaCamera has formally withdrawn its notice of nomination of candidates dated Jan. 14, as well as its request to add such candidates to the board, according to a schedule 13D filing with the Securities and Exchange Commission.

DellaCamera said it is encouraged by the prospective addition of a new, independent member to the Enzon board.

As previously reported, DellaCamera had nominated John (Jack) Geltosky, David Tendler and David Gale for election to Enzon's board.

In December, DellaCamera urged Enzon's board to review options to increase shareholder value.

DellaCamera beneficially owns 2,414,481 shares, or about by 5.5%, of the Bridgewater, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.